Improving Tardive Dyskinesia Management in Japan: Prevention, Diagnosis, and New Treatments
Tardive dyskinesia (TD) is underrecognized in Japan, partly due to cultural stigma and limited awareness among healthcare professionals. Early diagnosis is challenging, as TD may resemble other movement disorders, and it is often irreversible.
Managing Tardive Dyskinesia: A Case Study Highlighting Diagnosis, Treatment, and Prevention Strategies
The pathophysiology of tardive dyskinesia (TD) involves prolonged dopamine receptor blockade, leading to receptor supersensitivity and oxidative damage in the striatum.
Expert Panel: Routine Impact Assessments Key to Managing Tardive Dyskinesia
Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary movements that significantly affect physical, cognitive, and psychosocial functioning.
Study Highlights Major Impact of Tardive Dyskinesia, Urges Greater Awareness and Early Intervention
Researchers of a study aimed to evaluate the broad impact of tardive dyskinesia (TD) on patients’ physical, emotional, and social functioning.
Life with Tardive Dyskinesia: A Patient Journey
Keith Wapniarski’s life took a drastic turn after a car accident in 1986, which led to severe migraines and pain.
Tardive Dyskinesia Impact Scale Offers Comprehensive Patient Perspective on Physical and Socioemotional Impacts
Tardive dyskinesia (TD) is a movement disorder caused by prolonged use of dopamine receptor-blocking medications, significantly affecting physical, cognitive, and psychosocial functioning.
Experts Discuss Managing Co-Occurring Drug-Induced Parkinsonism and Tardive Dyskinesia
In a discussion led by Rakesh Jain, MD, MPH, experts Rajeev Kumar, MD, and Jonathan Meyer, MD, explored the complexities of treating patients with both drug-induced parkinsonism and tardive dyskinesia (TD). They emphasized the importance of reducing antipsychotic dosage when possible and using amantadine to manage parkinsonism without worsening TD. If dosage reduction isn’t feasible, switching to a weaker D2 blocker like clozapine was suggested.
Study Reveals Overprescription of Benztropine for Movement Disorders, Urges Better Guideline Adherence
Benztropine, an anticholinergic medication, is prescribed short-term for drug-induced movement disorders but can worsen tardive dyskinesia symptoms. Researchers of a study analyzed a large US medical claims database, identifying over 100,000 patients who began benztropine treatment between 2017-2020, and surveyed 350 healthcare providers about their prescribing habits.
Tardive Dyskinesia in Schizophrenia: Case Study Highlights Challenges and Treatment Strategies
Tardive dyskinesia (TD) syndromes involve abnormal involuntary movements, ranging from mild to severe, and are linked to increased mortality in schizophrenia. The incidence of TD is 5.5% with first-generation antipsychotics and 3.9% with second-generation antipsychotics, with long-term prevalence between 15% and 30%.
Exploring the Impact of Tardive Dyskinesia on Physical and Psychological Well-Being
This brief video explores tardive dyskinesia (TD) and its profound effects on both physical and psychological well-being. Involuntary movements can cause localized pain and lead to feelings of sadness, depression, and anxiety. These symptoms can diminish self-esteem, create feelings of hopelessness, and result in a loss of purpose. Social stigma further exacerbates these issues, as individuals with TD might be identified as mentally ill, affecting their mental health and leading to increased isolation.
